Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results.
David CallananRahul N KhuranaRaj K MaturiSunil PatelCharles C WykoffDavid A EichenbaumArshad M KhananiTarek HassanHanh BadgerShraddha MehtaGrace LeMayssa AttarJennifer SealXiao-Yan LiPublished in: Clinical ophthalmology (Auckland, N.Z.) (2023)
Abicipar produced using a modified manufacturing process showed a moderately lower incidence and severity of IOI compared with Phase 3 abicipar studies. Beneficial effects of treatment were demonstrated.